Varenicline for smoking cessation

Nausea severity and variation in nicotinic receptor genes

G. E. Swan, H. S. Javitz, L. M. Jack, J. Wessel, M. Michel, D. A. Hinds, R. P. Stokowksi, J. B. Mcclure, Sheryl L Catz, J. Richards, S. M. Zbikowski, M. Deprey, T. Mcafee, D. V. Conti, A. W. Bergen

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

This study evaluated association between common and rare sequence variants in 10 nicotinic acetylcholine receptor subunit genes and the severity of nausea 21 days after initiating the standard, Food and Drug Administration-approved varenicline regimen for smoking cessation. A total of 397 participants from a randomized clinical effectiveness trial with complete clinical and DNA resequencing data were included in the analysis (mean age49.2 years; 68.0% female). Evidence for significant association between common sequence variants in CHRNB2 and nausea severity was obtained after adjusting for age, gender and correlated tests (all P ACT 0.05). Individuals with the minor allele of CHRNB2 variants experienced less nausea than did those without the minor allele, consistent with previously reported findings for CHRNB2 and the occurrence of nausea and dizziness as a consequence of first smoking attempt in adolescents, and with the known neurophysiology of nausea. As nausea is the most common reason for discontinuance of varenicline, further pharmacogenetic investigations are warranted.

Original languageEnglish (US)
Pages (from-to)349-358
Number of pages10
JournalPharmacogenomics Journal
Volume12
Issue number4
DOIs
StatePublished - Aug 2012
Externally publishedYes

Fingerprint

Nicotinic Receptors
Smoking Cessation
Nausea
Genes
Alleles
Neurophysiology
Pharmacogenetics
Dizziness
United States Food and Drug Administration
Varenicline
Randomized Controlled Trials
Smoking
DNA

Keywords

  • adherence
  • nausea
  • smoking cessation
  • varenicline

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Genetics

Cite this

Swan, G. E., Javitz, H. S., Jack, L. M., Wessel, J., Michel, M., Hinds, D. A., ... Bergen, A. W. (2012). Varenicline for smoking cessation: Nausea severity and variation in nicotinic receptor genes. Pharmacogenomics Journal, 12(4), 349-358. https://doi.org/10.1038/tpj.2011.19

Varenicline for smoking cessation : Nausea severity and variation in nicotinic receptor genes. / Swan, G. E.; Javitz, H. S.; Jack, L. M.; Wessel, J.; Michel, M.; Hinds, D. A.; Stokowksi, R. P.; Mcclure, J. B.; Catz, Sheryl L; Richards, J.; Zbikowski, S. M.; Deprey, M.; Mcafee, T.; Conti, D. V.; Bergen, A. W.

In: Pharmacogenomics Journal, Vol. 12, No. 4, 08.2012, p. 349-358.

Research output: Contribution to journalArticle

Swan, GE, Javitz, HS, Jack, LM, Wessel, J, Michel, M, Hinds, DA, Stokowksi, RP, Mcclure, JB, Catz, SL, Richards, J, Zbikowski, SM, Deprey, M, Mcafee, T, Conti, DV & Bergen, AW 2012, 'Varenicline for smoking cessation: Nausea severity and variation in nicotinic receptor genes', Pharmacogenomics Journal, vol. 12, no. 4, pp. 349-358. https://doi.org/10.1038/tpj.2011.19
Swan, G. E. ; Javitz, H. S. ; Jack, L. M. ; Wessel, J. ; Michel, M. ; Hinds, D. A. ; Stokowksi, R. P. ; Mcclure, J. B. ; Catz, Sheryl L ; Richards, J. ; Zbikowski, S. M. ; Deprey, M. ; Mcafee, T. ; Conti, D. V. ; Bergen, A. W. / Varenicline for smoking cessation : Nausea severity and variation in nicotinic receptor genes. In: Pharmacogenomics Journal. 2012 ; Vol. 12, No. 4. pp. 349-358.
@article{9ff0084575f440bb83d1177eb3e5adc0,
title = "Varenicline for smoking cessation: Nausea severity and variation in nicotinic receptor genes",
abstract = "This study evaluated association between common and rare sequence variants in 10 nicotinic acetylcholine receptor subunit genes and the severity of nausea 21 days after initiating the standard, Food and Drug Administration-approved varenicline regimen for smoking cessation. A total of 397 participants from a randomized clinical effectiveness trial with complete clinical and DNA resequencing data were included in the analysis (mean age49.2 years; 68.0{\%} female). Evidence for significant association between common sequence variants in CHRNB2 and nausea severity was obtained after adjusting for age, gender and correlated tests (all P ACT 0.05). Individuals with the minor allele of CHRNB2 variants experienced less nausea than did those without the minor allele, consistent with previously reported findings for CHRNB2 and the occurrence of nausea and dizziness as a consequence of first smoking attempt in adolescents, and with the known neurophysiology of nausea. As nausea is the most common reason for discontinuance of varenicline, further pharmacogenetic investigations are warranted.",
keywords = "adherence, nausea, smoking cessation, varenicline",
author = "Swan, {G. E.} and Javitz, {H. S.} and Jack, {L. M.} and J. Wessel and M. Michel and Hinds, {D. A.} and Stokowksi, {R. P.} and Mcclure, {J. B.} and Catz, {Sheryl L} and J. Richards and Zbikowski, {S. M.} and M. Deprey and T. Mcafee and Conti, {D. V.} and Bergen, {A. W.}",
year = "2012",
month = "8",
doi = "10.1038/tpj.2011.19",
language = "English (US)",
volume = "12",
pages = "349--358",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Varenicline for smoking cessation

T2 - Nausea severity and variation in nicotinic receptor genes

AU - Swan, G. E.

AU - Javitz, H. S.

AU - Jack, L. M.

AU - Wessel, J.

AU - Michel, M.

AU - Hinds, D. A.

AU - Stokowksi, R. P.

AU - Mcclure, J. B.

AU - Catz, Sheryl L

AU - Richards, J.

AU - Zbikowski, S. M.

AU - Deprey, M.

AU - Mcafee, T.

AU - Conti, D. V.

AU - Bergen, A. W.

PY - 2012/8

Y1 - 2012/8

N2 - This study evaluated association between common and rare sequence variants in 10 nicotinic acetylcholine receptor subunit genes and the severity of nausea 21 days after initiating the standard, Food and Drug Administration-approved varenicline regimen for smoking cessation. A total of 397 participants from a randomized clinical effectiveness trial with complete clinical and DNA resequencing data were included in the analysis (mean age49.2 years; 68.0% female). Evidence for significant association between common sequence variants in CHRNB2 and nausea severity was obtained after adjusting for age, gender and correlated tests (all P ACT 0.05). Individuals with the minor allele of CHRNB2 variants experienced less nausea than did those without the minor allele, consistent with previously reported findings for CHRNB2 and the occurrence of nausea and dizziness as a consequence of first smoking attempt in adolescents, and with the known neurophysiology of nausea. As nausea is the most common reason for discontinuance of varenicline, further pharmacogenetic investigations are warranted.

AB - This study evaluated association between common and rare sequence variants in 10 nicotinic acetylcholine receptor subunit genes and the severity of nausea 21 days after initiating the standard, Food and Drug Administration-approved varenicline regimen for smoking cessation. A total of 397 participants from a randomized clinical effectiveness trial with complete clinical and DNA resequencing data were included in the analysis (mean age49.2 years; 68.0% female). Evidence for significant association between common sequence variants in CHRNB2 and nausea severity was obtained after adjusting for age, gender and correlated tests (all P ACT 0.05). Individuals with the minor allele of CHRNB2 variants experienced less nausea than did those without the minor allele, consistent with previously reported findings for CHRNB2 and the occurrence of nausea and dizziness as a consequence of first smoking attempt in adolescents, and with the known neurophysiology of nausea. As nausea is the most common reason for discontinuance of varenicline, further pharmacogenetic investigations are warranted.

KW - adherence

KW - nausea

KW - smoking cessation

KW - varenicline

UR - http://www.scopus.com/inward/record.url?scp=84864360423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864360423&partnerID=8YFLogxK

U2 - 10.1038/tpj.2011.19

DO - 10.1038/tpj.2011.19

M3 - Article

VL - 12

SP - 349

EP - 358

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 4

ER -